Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Current Liabilities (2016 - 2025)

Karyopharm Therapeutics' Total Current Liabilities history spans 14 years, with the latest figure at $92.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities changed 0.22% year-over-year to $92.1 million; the TTM value through Dec 2025 reached $92.1 million, changed 0.22%, while the annual FY2025 figure was $92.1 million, 0.22% changed from the prior year.
  • Total Current Liabilities reached $92.1 million in Q4 2025 per KPTI's latest filing, up from $87.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $99.2 million in Q2 2025 to a low of $57.6 million in Q2 2024.
  • Average Total Current Liabilities over 5 years is $70.8 million, with a median of $65.6 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: dropped 10.59% in 2022, then soared 72.19% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $73.7 million in 2021, then decreased by 10.59% to $65.9 million in 2022, then grew by 5.42% to $69.5 million in 2023, then surged by 32.79% to $92.3 million in 2024, then fell by 0.22% to $92.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Total Current Liabilities are $92.1 million (Q4 2025), $87.2 million (Q3 2025), and $99.2 million (Q2 2025).